These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31606419)

  • 1. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
    Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
    Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
    Laetsch TW; Maude SL; Rives S; Hiramatsu H; Bittencourt H; Bader P; Baruchel A; Boyer M; De Moerloose B; Qayed M; Buechner J; Pulsipher MA; Myers GD; Stefanski HE; Martin PL; Nemecek E; Peters C; Yanik G; Khaw SL; Davis KL; Krueger J; Balduzzi A; Boissel N; Tiwari R; O'Donovan D; Grupp SA
    J Clin Oncol; 2023 Mar; 41(9):1664-1669. PubMed ID: 36399695
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
    Levine JE; Grupp SA; Pulsipher MA; Dietz AC; Rives S; Myers GD; August KJ; Verneris MR; Buechner J; Laetsch TW; Bittencourt H; Baruchel A; Boyer MW; De Moerloose B; Qayed M; Davies SM; Phillips CL; Driscoll TA; Bader P; Schlis K; Wood PA; Mody R; Yi L; Leung M; Eldjerou LK; June CH; Maude SL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34353848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
    Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
    Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
    Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
    Front Immunol; 2023; 14():1280580. PubMed ID: 38292483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
    Curran KJ; Margossian SP; Kernan NA; Silverman LB; Williams DA; Shukla N; Kobos R; Forlenza CJ; Steinherz P; Prockop S; Boulad F; Spitzer B; Cancio MI; Boelens JJ; Kung AL; Khakoo Y; Szenes V; Park JH; Sauter CS; Heller G; Wang X; Senechal B; O'Reilly RJ; Riviere I; Sadelain M; Brentjens RJ
    Blood; 2019 Dec; 134(26):2361-2368. PubMed ID: 31650176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
    Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
    Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
    Barsan V; Li Y; Prabhu S; Baggott C; Nguyen K; Pacenta H; Phillips CL; Rossoff J; Stefanski H; Talano JA; Moskop A; Baumeister S; Verneris MR; Myers GD; Karras NA; Cooper S; Qayed M; Hermiston M; Satwani P; Krupski C; Keating A; Fabrizio V; Chinnabhandar V; Kunicki M; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
    EClinicalMedicine; 2023 Nov; 65():102268. PubMed ID: 37954907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    V Stackelberg A; Jäschke K; Jousseaume E; Templin C; Jeratsch U; Kosmides D; Steffen I; Gökbuget N; Peters C
    Leukemia; 2023 Dec; 37(12):2346-2355. PubMed ID: 37880478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
    Dreyling M; Fowler NH; Dickinson M; Martinez-Lopez J; Kolstad A; Butler J; Ghosh M; Popplewell L; Chavez JC; Bachy E; Kato K; Harigae H; Kersten MJ; Andreadis C; Riedell PA; Ho PJ; Pérez-Simón JA; Chen AI; Nastoupil LJ; von Tresckow B; María Ferreri AJ; Teshima T; Patten PEM; McGuirk JP; Petzer AL; Offner F; Viardot A; Zinzani PL; Malladi R; Paule I; Zia A; Awasthi R; Han X; Germano D; O'Donovan D; Ramos R; Maier HJ; Masood A; Thieblemont C; Schuster SJ
    Blood; 2024 Apr; 143(17):1713-1725. PubMed ID: 38194692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
    Fowler NH; Dickinson M; Dreyling M; Martinez-Lopez J; Kolstad A; Butler J; Ghosh M; Popplewell L; Chavez JC; Bachy E; Kato K; Harigae H; Kersten MJ; Andreadis C; Riedell PA; Ho PJ; Pérez-Simón JA; Chen AI; Nastoupil LJ; von Tresckow B; Ferreri AJM; Teshima T; Patten PEM; McGuirk JP; Petzer AL; Offner F; Viardot A; Zinzani PL; Malladi R; Zia A; Awasthi R; Masood A; Anak O; Schuster SJ; Thieblemont C
    Nat Med; 2022 Feb; 28(2):325-332. PubMed ID: 34921238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Apr; ():. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
    Tong WH; Mertens BJ
    J Clin Oncol; 2023 May; 41(13):2450-2451. PubMed ID: 36898080
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
    Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
    Front Immunol; 2024; 15():1373852. PubMed ID: 38384474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
    Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):194-202. PubMed ID: 38052709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
    Gye A; Lourenco RA; Goodall S
    Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.
    Forsberg MH; Das A; Saha K; Capitini CM
    Ther Clin Risk Manag; 2018; 14():1573-1584. PubMed ID: 30233192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.